Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products Prothena will receive a worldwide, exclusive license to use the xB 3 platform with an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. However, FINRA regulations require all readers to sign onto our site. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY